. Military Space News .
EPIDEMICS
'Mutant flu' could lead to more effective vaccine: study
by Staff Writers
Miami (AFP) Jan 18, 2018


Experiments in lab animals have shown signs of success for a newly engineered flu virus that may lead one day to a more effective vaccine, researchers said Thursday.

Trials in humans are still a long way off, but the report in the US journal Science earned praise from experts who described it as a promising first step toward better prevention of the flu.

The World Health Organization considers the flu a major public health concern because it infects up to five million people with severe illness each year and causes up to 650,000 deaths.

"Because the variations of seasonal influenza viruses can be unpredictable, current vaccines may not provide effective protection against them," said senior author Ren Sun, a professor of molecular and medical pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

"Previous pandemics and recent outbreaks of avian influenza highlight the need to develop vaccines that offer broader, more effective protection."

Scientists arrived at the new approach by studying the genome of the flu virus and finding eight locations where they could disable its interferon-evasion functions, which affect whether a host can fight the illness or not.

Regular flu viruses are known for their ability to evade the immune system, but this engineered virus showed it "is hypersensitive to one of the body's primary immune defense mechanisms," said the report.

The mutant virus can "escape type 1 interferon (IFN-1) function, the body's first line of defense against viruses."

The engineered influenza virus "induced strong immune responses" in mice and ferrets without causing them to become ill, said the report.

It also protected against infection by different strains of the influenza virus.

More animal studies are planned before any vaccine based on the approach can be tried in people.

Jonathan Ball, professor of Molecular Virology at the University of Nottingham, described the paper as a "neat bit of science."

"There's still lots of work to do in order to progress this exciting development down the vaccine development pipeline," said Ball, who was not involved in the research.

"These experiments were performed in laboratory animals and the proof of the pudding will be how the mutant virus performs in humans, especially those who have been exposed to multiple strains of virus and might already have built up a degree of immunity."

Peter Openshaw, professor of experimental medicine at Imperial College London, described the work as a "collaborative tour de force between groups in North America and China," that could lead the way to a universal flu vaccine.

"This advanced approach combines state of the art virology with incisive immunological techniques, potentially leading to greatly improved vaccines in the future," he said.

However, there are "many hurdles to be overcome moving from pre-clinical through to clinical testing and ultimately to incorporation into standard vaccine schedules."

Currently, influenza vaccines must be changed every year because the viruses are constantly evolving. Their effectiveness typically ranges from 30-60 percent.

EPIDEMICS
TSRI scientists discover workings of first promising Marburg virus treatment
La Jolla CA (SPX) Jan 11, 2018
With a mortality rate of up to 88 percent, Marburg virus can rip through a community in days. In 2005, an outbreak of Marburg virus struck a pediatric ward in the country of Angola. With no treatment available, doctors struggled to help as the virus killed 329 of 374 infected patients. Now, scientists at The Scripps Research Institute (TSRI) have discovered the workings of the first promis ... read more

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola


Thanks for being here;
We need your help. The Space Media Network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceMediaNetwork Contributor
$5 Billed Once


credit card or paypal
SpaceMediaNetwork Monthly Supporter
$5 Billed Monthly


paypal only


Comment using your Disqus, Facebook, Google or Twitter login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

EPIDEMICS
Hawaii 'missile alert' sparks anger, demands for answers

US official defends early-warning systems after Hawaii 'failure'

Lockheed Martin demonstrates next generation Aegis Ashore Solution

SBIRS GEO Flight-4 missile warning satellite encapsulated for launch

EPIDEMICS
India likely to revive mega missile deal with Israel

State Department approves $133.3M missile sale to Japan

Navy awards Raytheon with $27M contract for SM-2 missiles

Raytheon to support Evolved Sea Sparrow Missile for U.S., NATO partners

EPIDEMICS
Boeing unveils UAV prototype for cargo, logistics use

Russia's army warns of 'terrorist' drones after attacks

Air Force to upgrade Reaper drone fleet as the Predator begins retirement

DARPA working on collaborative autonomy for UAVs and Drones

EPIDEMICS
Map of ionospheric disturbances to help improve radio network systems

Military defense market faces new challenges to acquiring SatCom platforms

Harris contracted by Army for radios for security force assistance brigades

Joint Hellas-Sat-4 and SaudiGeoSat-1 satellite ready for environmental tests

EPIDEMICS
UK army seeks recruits by offering emotional support

US troops stage #MeTooMilitary protest outside Pentagon

Too fat to march: Spanish Legion soldiers put on diet

Environmentally safe red glare rocket changes fireworks, soldier technology

EPIDEMICS
N. Korea steps up tunnelling at nuclear test site: monitor

Airbus fined 104 mn euros over Taiwan missile affair

Congress to receive update from Pentagon as agency audit begins

Netanyahu set to lead trade task force to India

EPIDEMICS
Philippines to protest over China activity on reclaimed reef

India steps up China border patrols, vows to handle 'assertiveness'

India vows to handle China's 'assertiveness'

Japan protests after Chinese frigate sails near disputed isles

EPIDEMICS
Silver nanoparticles take spectroscopy to new dimension

Researchers find simpler way to deposit magnetic iron oxide onto gold nanorods

Discovery sets new world standard in nano generators

A 100-fold leap to GigaDalton DNA nanotech









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.